title: Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases.
abstract: The demonstration that immune and epithelial cells can discriminate between different microbial and bioactive plant species has extended the known mechanism(s) of action of nutraceuticals and probiotics beyond simple nutrition and/or antimicrobial effects. The progressive unravelling of these plant and bacterial effects on systemic immune and intestinal epithelial cell function has led to new credence for the use of probiotics and nutraceuticals in clinical medicine. Level I evidence now exists for the therapeutic use of probiotics in infectious diarrhea in children, recurrent Clostridium difficile-induced infections and post-operative pouchitis. Additional evidence is being acquired for the use of probiotics in other gastrointestinal infections, irritable bowel syndrome and inflammatory bowel disease. Not all individual probiotic strains have the same efficacy, and future clinical trials may focus on multistrain preparations agents with known efficacy. The use of nutraceuticals and probiotics as therapeutic agents for gastrointestinal disorders is rapidly moving into clinical usage. Scientific studies are providing mechanisms of action to explain the therapeutic effects, and randomized controlled trials are providing the necessary evidence for their incorporation into the therapeutic armamentarium.
authors.affiliation: Division of Gastroenterology, University of Alberta, 6146 Dentistry Pharmacy, Edmonton, Alberta T6G 2N8, Canada.
authors.forename: Robert
authors.initials: R
authors.lastname: Penner
authors.forename: Richard N
authors.initials: RN
authors.lastname: Fedorak
authors.forename: Karen L
authors.initials: KL
authors.lastname: Madsen
mesh_terms: D015179:Colorectal Neoplasms / Q000628:therapy; D003967:Diarrhea / Q000628:therapy; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use; D005767:Gastrointestinal Diseases / Q000628:therapy*; D016481:Helicobacter Infections / Q000628:therapy; D016480:Helicobacter pylori; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000628:therapy; D043183:Irritable Bowel Syndrome / Q000628:therapy; D044623:Nutrition Therapy; D010195:Pancreatitis / Q000628:therapy; D019936:Probiotics / Q000627:therapeutic use*
chemical_list: D015525:Fatty Acids, Omega-3